Literature DB >> 9708771

Secrecy and transparency of medicines licensing in the EU.

J Abraham1, G Lewis.   

Abstract

Mesh：

Year:  1998        PMID： 9708771     DOI： 10.1016/S0140-6736(97)11282-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.

Authors:  P Impicciatore; I Choonara
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  The science and politics of medicines control.

Authors:  John Abraham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.

Authors:  K Abbasi; A Herxheimer
Journal:  BMJ       Date:  1998-10-03

4.  Protective effect of ginsenosides Rg1 and Re on lipopolysaccharide-induced sepsis by competitive binding to Toll-like receptor 4.

Authors:  Fei Su; Yin Xue; Yuemin Wang; Lili Zhang; Wangxue Chen; Songhua Hu
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.